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The DNA sequence 5’CG (CpG) is self-complementary
and can exist in three major chemical forms depending
on the modification status of its cytosine moiety. To
understand the functional significance of the CpG dinu-
cleotide, we study proteins that bind either its methy-
lated or unmethylated form. These proteins are likely
mediators of CpG signalling that influence chromatin
modification and thereby genome activity. The local
density of CpG varies dramatically within genomic
DNA. In the bulk genome CpG is rare and highly
methylated, but in so-called “CpG islands” (CGIs) it is
dense and usually non-methylated. A signature histone
mark at non-methylated CGIs and also at transcription-
ally active genes is trimethylation of histone H3 lysine 4.
We are exploring the mechanisms by which DNA
sequence features that are shared by all CGIs influence
this and other epigenetic marks. In contrast, proteins
that interact with methyl-CpG are thought to promote
gene silencing by recruiting transcriptional corepressors.
In particular mutations in the gene for the methyl-CpG
binding protein MeCP2 cause the autism spectrum disor-
der Rett Syndrome. By studying MeCP2 we are learning
about its partner proteins that mediate effects on chroma-
tin. These findings allow us to evaluate competing models
for MeCP2 function and they illuminate the biology of
DNA methylation and the molecular basis of this neurolo-
gical condition.
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